251 related articles for article (PubMed ID: 14635069)
1. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis.
Jani AB; Kao J; Hellman S
Cancer; 2003 Dec; 98(11):2351-61. PubMed ID: 14635069
[TBL] [Abstract][Full Text] [Related]
2. Hormone therapy and radiotherapy for early prostate cancer: a utility-adjusted number needed to treat (NNT) analysis.
Jani AB; Kao J; Heimann R; Hellman S
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):687-94. PubMed ID: 15708246
[TBL] [Abstract][Full Text] [Related]
3. Androgen ablation adjuvant to postprostatectomy radiotherapy: complication-adjusted number needed to treat analysis.
Jani AB; Sokoloff M; Shalhav A; Stadler W
Urology; 2004 Nov; 64(5):976-81. PubMed ID: 15533489
[TBL] [Abstract][Full Text] [Related]
4. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
Bria E; Cuppone F; Giannarelli D; Milella M; Ruggeri EM; Sperduti I; Pinnarò P; Terzoli E; Cognetti F; Carlini P
Cancer; 2009 Aug; 115(15):3446-56. PubMed ID: 19484790
[TBL] [Abstract][Full Text] [Related]
5. Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis.
Jani AB; Kao J
Cancer; 2005 May; 103(9):1833-42. PubMed ID: 15756656
[TBL] [Abstract][Full Text] [Related]
6. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
[TBL] [Abstract][Full Text] [Related]
7. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
8. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
[TBL] [Abstract][Full Text] [Related]
10. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate.
D'Amico AV; Denham JW; Bolla M; Collette L; Lamb DS; Tai KH; Steigler A; Chen MH
Cancer; 2007 May; 109(10):2004-10. PubMed ID: 17397033
[TBL] [Abstract][Full Text] [Related]
11. [Combined hormonotherapy with external beam radiotherapy in locally advanced prostate cancer: do side effects overlap the advantages?].
Drouin SJ; Rouprêt M; Bossi A; Bolla M
Prog Urol; 2010 Jun; 20 Suppl 3():S186-91. PubMed ID: 20620963
[TBL] [Abstract][Full Text] [Related]
12. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
13. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.
Hachiya T; Akakura K; Saito S; Shinohara N; Sato K; Harada M; Kato T; Okada K
BJU Int; 2005 Mar; 95(4):534-40. PubMed ID: 15705075
[TBL] [Abstract][Full Text] [Related]
15. Early versus delayed endocrine therapy for prostate cancer.
Schröder FH
Endocr Relat Cancer; 2007 Mar; 14(1):1-11. PubMed ID: 17395971
[TBL] [Abstract][Full Text] [Related]
16. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
Rübben H
Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
[TBL] [Abstract][Full Text] [Related]
17. [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].
Bolla M; Fourneret P; Beneyton V; Tessier A; Jover F; Verry C
Cancer Radiother; 2010 Oct; 14(6-7):510-4. PubMed ID: 20728391
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
Milecki P; Kwias Z; Martenka DJ
Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
[TBL] [Abstract][Full Text] [Related]
19. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
Teillac P; Bono AV; Irani J; Wirth MP; Zlotta AR
Clin Ther; 2005 Mar; 27(3):273-85. PubMed ID: 15878381
[TBL] [Abstract][Full Text] [Related]
20. Technological advances in radiotherapy for the treatment of localised prostate cancer.
Mangar SA; Huddart RA; Parker CC; Dearnaley DP; Khoo VS; Horwich A
Eur J Cancer; 2005 Apr; 41(6):908-21. PubMed ID: 15808957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
